(Gastric Cancer) Is Nivolumab + Ipilimumab Effective?
Medical Supporter — Avis d’information
Cet article est une synthèse d’informations médicales internationales et ne constitue pas un avis médical ; il ne remplace pas le diagnostic ni le plan de traitement de votre médecin traitant. Les informations présentées sont compilées à partir de publications publiques et de déclarations officielles d’établissements médicaux japonais ; l’adéquation et les résultats de toute thérapie varient selon chaque patient et doivent être évalués individuellement par un médecin qualifié.
- August 26, 2022
- Read time: 1 minute
On August 3, 2022, Thierry André et al. of Saint-Antoine Hospital published in the medical journal Journal of Clinical Oncology the efficacy and safety results of nivolumab (Opdivo) + ipilimumab (Yervoy) as neoadjuvant chemotherapy followed by nivolumab monotherapy in patients with dMMR and MSI-H locally advanced gastric cancer and gastroesophageal junction adenocarcinoma in the GERCOR NEONIPIGA Phase 2 clinical trial.
The GERCOR NEONIPIGA Phase 2 clinical trial administered nivolumab (2-week cycle, 240 mg per dose, 6 cycles total) + ipilimumab (6-week cycle, 1 mg/kg per dose, 2 cycles total) as preoperative therapy to dMMR and MSI-H locally advanced gastric cancer and gastroesophageal junction adenocarcinoma patients (N=32), followed by postoperative nivolumab (4-week cycle, 480 mg per dose). The primary endpoint was complete response rate.
In this trial, the median patient age was 65.5 years. Clinical staging was cT2-T3N0 (N=9), cT2-T3N1 (N=22), and cT3N1M1 (N=1). Results at a median follow-up of 14.9 months were as follows.
The incidence of Grade 3–4 adverse events during preoperative treatment was 19% (N=6). Among the 29 patients who underwent surgery after treatment, all 29 achieved R0 resection, with a complete response rate of 58.6% (N=17).
Based on the GERCOR NEONIPIGA trial results, Thierry André et al. concluded that nivolumab + ipilimumab as neoadjuvant chemotherapy had good tolerability and demonstrated a high complete response rate.
Source: https://ascopubs.org/doi/full/10.1200/JCO.22.00686
Medical Supporter was formerly certified as an international medical visa guarantor by Japan's Ministry of Foreign Affairs and the Ministry of Economy, Trade and Industry (B-066).
Vous envisagez des soins au Japon ? Besoin d’informations et d’aide ?
Nous vous aidons à rassembler les informations nécessaires pour un déplacement médical au Japon, à contacter les établissements japonais et à organiser une consultation de second avis.La première consultation est gratuite ; un conseiller vous aide à clarifier les prochaines étapes.
Figure 1
Figure 2
Figure 3
Figure 4